α-Emitting cancer therapy using 211At-AAMT targeting LAT1

44Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

α-Methyl-l-tyrosine (AMT) has a high affinity for the cancer-specific l-type amino acid transporter 1 (LAT1). Therefore, we established an anti-cancer therapy, with 211At-labeled α-methyl-l-tyrosine (211At-AAMT) as a carrier of 211At into tumors. 211At-AAMT had high affinity for LAT1, inhibited tumor cell growth, and induced DNA double-stranded breaks in vitro. We evaluated the accumulation of 211At-AAMT in vivo and the role of LAT1. Treatment with 0.4 MBq/mouse 211At-AAMT inhibited tumor growth in the PANC-1 tumor model and 1 MBq/mouse 211At-AAMT inhibited metastasis in the lung of the B16F10 metastasis model. Our results suggested that 211At would be useful for anti-cancer therapy and that LAT1 is suitable as a target for radionuclide therapy.

Cite

CITATION STYLE

APA

Kaneda-Nakashima, K., Zhang, Z. J., Manabe, Y., Shimoyama, A., Kabayama, K., Watabe, T., … Shinohara, A. (2021). α-Emitting cancer therapy using 211At-AAMT targeting LAT1. Cancer Science, 112(3), 1132–1140. https://doi.org/10.1111/cas.14761

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free